Stay updated with breaking news from Ron Squarer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 –– Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 –– INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-...
Strengthens the Board with the election of Robert W. Azelby as director
To the shareholders of ADC Therapeutics SA Invitation to the Annual General Meeting Date and Time: Wednesday, June 14, 2023, at 4:00 a.m. EDT / 10:00 a.m. CEST ... | May 5, 2023
Ameet Mallik, Chief Executive Officer of ADC Therapeutics, also joins the Board ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari